+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07266428

Phase 12A Study Evaluating OTP-01, a Dual PD-1VEGFR2 Antibody, in Adults with Advanced Solid Tumors

Led by Ottimo Pharma Limited · Updated on 2026-10-09

170

Participants Needed

21

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating OTP-01, a dual paratopic PD-1VEGFR2 antibody, in adults with advanced solid tumors to determine the best dose, understand how it is tolerated, and identify any side effects. The study also aims to see whether OTP-01 can shrink tumors and how the body processes the drug by measuring its levels in the blood. This trial is a Phase 12A study led by Ottimo Pharma Limited. Participants receive OTP-01 through an intravenous infusion, with doses spaced out and given no more than once a week. The study includes a dose escalation phase and a dose expansion phase, where participants may also opt for tumor biopsies before and after treatment to help researchers understand the drugs effects on cancer and the immune system. Tumor scans are done at the start and regularly during the study to monitor changes. During the trial, participants undergo frequent blood tests initially to check safety and drug levels, which become less frequent over time. Researchers measure adverse events, tumor responses, and progression-free survival up to 36 months. Optional tumor biopsies are voluntary and do not affect participation. The total study duration can be up to three years, with ongoing monitoring of safety and effectiveness throughout.

CONDITIONS

Brief Title

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here